459 Studies Now Enrolling
Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice)
MiChoice: Making Informed Choices on Incorporating Chemoprevention Into Care
| Sponsor: | Southwest Oncology Group |
| Enrolling: | Female Patients Only |
| IRB Number: | AAAT2911 |
| U.S. Govt. ID: | NCT04496739 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The study is being done to answer the following question: How can we best help women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) and their healthcare providers make informed decisions about whether to take breast cancer risk-reducing pills (drugs to slow or prevent breast cancer from developing)? Participants in this study will learn about their breast cancer risk, receive educational materials, and allow us to share their breast cancer risk information with their doctor.
This study is closed
Do You Qualify?
| Are you a woman between the ages of 35 and 74? | Yes | No |
| Have you been diagnosed with atypical hyperplasia (AH, abnormal cells in the breast) or lobular carcinoma in situ (LCIS)? | Yes | No |
| Do you have no personal history of breast cancer and no previously used breast cancer risk-reducing pills, such as tamoxifen? | Yes | No |